NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Open in Screener

ALT

Altimmune Inc

Apr 04 • 04:00PM ET

4.24

Dollar change -0.22
Percentage change -4.93	%

Healthcare • Biotechnology • USA • NASD

Peers: NVAX INO VXRT XFOR ADMA AGEN BCRX ANIX DTIL AVIR

| Held by: VTI IWM XBI VXF IBB VTWO IWO VHT IWN IWC

Index	RUT	P/E	-	EPS (ttm)	-1.34	Insider Own	1.04%	Shs Outstand	77.01M	Perf Week	-20.30%
Market Cap	326.54M	Forward P/E	-	EPS next Y	-1.66	Insider Trans	1.39%	Shs Float	76.21M	Perf Month	-24.15%
Income	-95.06M	PEG	-	EPS next Q	-0.36	Inst Own	53.13%	Short Float	29.46%	Perf Quarter	-40.37%
Sales	0.02M	P/S	16326.85	EPS this Y	-6.99%	Inst Trans	2.51%	Short Ratio	8.93	Perf Half Y	-32.38%
Book/sh	1.71	P/B	2.48	EPS next Y	-16.10%	ROA	-54.33%	Short Interest	22.45M	Perf Year	-54.36%
Cash/sh	1.71	P/C	2.48	EPS next 5Y	0.77%	ROE	-59.86%	52W Range	4.43 - 11.16	Perf YTD	-41.19%
Dividend Est.	-	P/FCF	-	EPS past 5Y	3.48%	ROI	-76.10%	52W High	-62.01%	Beta	1.17
Dividend TTM	-	Quick Ratio	13.10	Sales past 5Y	104.92%	Gross Margin	-1090.00%	52W Low	-4.29%	ATR (14)	0.38
Dividend Ex-Date	Jan 20, 2017	Current Ratio	13.10	EPS Y/Y TTM	18.58%	Oper. Margin	-515860.00%	RSI (14)	27.31	Volatility	7.39% 6.46%
Employees	59	Debt/Eq	0.01	Sales Y/Y TTM	-95.31%	Profit Margin	-475295.00%	Recom	1.20	Target Price	22.38
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	39.92%	Payout	-	Rel Volume	1.19	Prev Close	4.46
Sales Surprise	-	EPS Surprise	0.75%	Sales Q/Q	-86.49%	Earnings	Feb 27 BMO	Avg Volume	2.52M	Price	4.24
SMA20	-21.49%	SMA50	-29.58%	SMA200	-38.23%	Trades		Volume	2,984,958	Change	-4.93%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-25	Initiated	William Blair	Mkt Perform
Jan-08-25	Initiated	Stifel	Buy	$18
Nov-12-24	Initiated	UBS	Buy	$26
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral	$13
Mar-22-23	Downgrade	Goldman	Buy → Neutral	$20 → $6
Dec-01-22	Initiated	Goldman	Buy	$20
Dec-29-21	Resumed	Jefferies	Buy	$30
Jun-02-21	Initiated	H.C. Wainwright	Buy	$35
Feb-11-21	Initiated	Guggenheim	Buy	$36
Dec-14-20	Initiated	Jefferies	Buy	$25
Nov-12-20	Reiterated	B. Riley Securities	Buy	$31 → $28
Sep-25-20	Initiated	B. Riley FBR	Buy	$31
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight	$80
Jul-28-20	Initiated	JMP Securities	Mkt Outperform	$50
Feb-24-20	Resumed	ROTH Capital	Buy	$13
Jul-19-19	Initiated	ROTH Capital	Buy	$8.30
Oct-09-17	Initiated	Piper Jaffray	Overweight	$6

Show Previous Ratings

Mar-22-25 06:44AM	Buying These Dirt-Cheap Stocks Could Be a Brilliant Move (Motley Fool)
Mar-19-25 04:33PM	Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts (InsiderMonkey)
Mar-06-25 07:30AM	Altimmune to Host Virtual R&D Day on March 13, 2025 (GlobeNewswire)
Mar-03-25 07:30AM	Altimmune to Participate in the Leerink Global Healthcare Conference (GlobeNewswire) -9.92%
Feb-27-25 07:00AM	Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire) +8.08%
07:30AM	Loading…
Feb-25-25 07:30AM	Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors (GlobeNewswire)
Feb-20-25 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 (GlobeNewswire)
Jan-29-25 07:30AM	Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-28-24 03:39PM	Jim Cramer on Altimmune, Inc. (ALT): and#8216;Healthcare Is So Out Of Fashion' (Insider Monkey)
Dec-19-24 07:30AM	Altimmune Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-17-24 08:13PM	Lightning Round: Ford's warranty problems will come back to haunt it, says Jim Cramer (CNBC TV) -6.67% -5.95%
Dec-03-24 06:22PM	Altimmune CEO on what's next for its experimental obesity drug (CNBC TV) +12.06%
Dec-02-24 07:30AM	Altimmune to Present at the Cachexia Regulatory and Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders (GlobeNewswire)
07:30AM	Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders (GlobeNewswire)
Nov-26-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
11:00AM	Loading…
Nov-15-24 11:00AM	Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024 (GlobeNewswire) -9.99%
Nov-12-24 07:00AM	Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +29.12%
Nov-11-24 07:30AM	Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
07:30AM	Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-24 07:30AM	Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity (GlobeNewswire)
Nov-06-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 07:30AM	Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (GlobeNewswire)
Oct-15-24 08:00AM	Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting 2024 (GlobeNewswire) +9.49%
Oct-01-24 07:30AM	Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference (GlobeNewswire)
Sep-30-24 07:30AM	Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire) -5.10%
Sep-10-24 01:09PM	CORRECTION Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire) +9.09%
07:45AM	Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-03-24 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Aug-08-24 07:00AM	Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +15.09%
Aug-07-24 07:00AM	CytoSorbents to Report Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -7.02%
07:30AM	Loading…
Aug-01-24 07:30AM	Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (GlobeNewswire)
Jul-25-24 07:30AM	Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology (GlobeNewswire) +6.70%
Jul-09-24 06:42AM	7 Bullish Stock Picks With the Potential to Turn $5K Into $50K (InvestorPlace)
Jul-06-24 08:00AM	The 7 Best Under $10 Stocks to Buy in July 2024 (InvestorPlace)
Jul-02-24 07:30AM	Altimmune to Participate at Leerink Partners Therapeutics Forum (GlobeNewswire) -6.39%
Jun-28-24 10:09AM	The 3 Smartest Biotech Stocks to Buy With $5K Right Now (InvestorPlace)
01:55AM	Altimmune, Inc. (ALT): Why Are Hedge Funds Shorting This Biopharmaceutical Stock? (Insider Monkey)
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey) -15.59%
07:30AM	Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt (GlobeNewswire)
Jun-24-24 06:02PM	Crypto under pressure, Good Buy or Goodbye: Market Domination (Yahoo Finance Video) +11.39%
03:52PM	Altimmune reports positive results in weight-loss drug trial (Yahoo Finance Video)
11:13AM	BITF Stock Alert: Riot Platforms Is Changing Its Approach to Take Over Bitfarms (InvestorPlace)
10:56AM	ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings (InvestorPlace)
Jun-23-24 01:45PM	Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
Jun-22-24 04:45PM	Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association's 84th Annual Scientific Sessions (GlobeNewswire)
Jun-21-24 05:45AM	Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT (PR Newswire) +7.91%
Jun-20-24 07:30AM	Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways (GlobeNewswire)
Jun-18-24 07:30AM	Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions (GlobeNewswire)
Jun-12-24 10:00AM	3 Stocks Quietly Preparing for a 10X Surge: June Edition (InvestorPlace)
Jun-05-24 07:00AM	Altimmune Presents Data at EASL International Liver Congress 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-29-24 07:31AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
07:30AM	Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress 2024 (GlobeNewswire)
May-27-24 02:56PM	The Penny Stock Prophecy: 3 Overlooked Stocks Primed to Pop (InvestorPlace)
May-23-24 05:45AM	Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT (PR Newswire) -6.34%
May-21-24 02:53PM	Altimmune, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information ALT (GlobeNewswire)
09:00AM	Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM) (PR Newswire)
May-20-24 03:01PM	Robbins LLP Urges Altimmune, Inc. (ALT) Stockholders With Large Losses to Contact the Firm for Information About Their Rights (Business Wire)
May-17-24 06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace) -10.00%
May-15-24 05:45AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT (PR Newswire) +13.43%
May-14-24 12:47PM	Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights ALT (GlobeNewswire) +6.11%
May-10-24 03:58PM	Altimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Call Transcript (Insider Monkey) -6.48%
May-09-24 11:57AM	ALT Stock Earnings: Altimmune Beats EPS for Q1 2024 (InvestorPlace) +7.82%
07:00AM	Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
May-08-24 08:50AM	Altimmune, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire)
May-07-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-02-24 07:30AM	Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 (GlobeNewswire)
May-01-24 07:30AM	Altimmune to Participate at Two Upcoming Conferences (GlobeNewswire) +7.94%
Apr-25-24 05:24PM	Altimmune Statement on the Passing of Dr. Stephen Harrison (GlobeNewswire)
Mar-29-24 12:00PM	Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Mar-28-24 10:49AM	Altimmune, Inc. (NASDAQ:ALT) Q4 2023 Earnings Call Transcript (Insider Monkey) +14.51%
Mar-27-24 06:29PM	A Novo Nordisk competitor teased a weight loss drug that minimizes muscle loss seen in other drugs (Quartz)
11:53AM	ALT Stock Earnings: Altimmune Beats EPS for Q4 2023 (InvestorPlace)
07:58AM	Altimmune bails on hepatitis B after phase 2 data disappoint, quashing partnering plans (FierceBiotech.com)
07:00AM	Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-20-24 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024 (GlobeNewswire) +6.86%
Feb-26-24 09:26AM	Why Is Altimmune (ALT) Stock Up 14% Today? (InvestorPlace) +23.04%
Feb-20-24 10:26AM	Altimmune (ALT) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-13-24 03:07PM	Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report (InvestorPlace) -18.65%
Jan-02-24 07:30AM	Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024 (GlobeNewswire) -6.49%
Dec-01-23 11:45AM	Why Is Altimmune (ALT) Stock Up 43% Today? (InvestorPlace) +12.97%
04:47AM	Altimmune, seeking edge on Lilly and Novo, puts heart health at center of phase 2 obesity data drop (FierceBiotech.com)
Nov-30-23 04:24PM	Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide (GlobeNewswire)
Nov-08-23 09:15AM	Altimmune, Inc. (NASDAQ:ALT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 07:00AM	Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Oct-31-23 07:30AM	Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023 (GlobeNewswire)
Oct-26-23 07:30AM	Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH) (GlobeNewswire)
Oct-25-23 07:30AM	Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting 2023 (GlobeNewswire)
Oct-17-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Sep-26-23 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-12-23 07:30AM	Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight (GlobeNewswire) +7.41%
Aug-30-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-03-23 07:30AM	Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023 (GlobeNewswire)
Aug-01-23 07:30AM	Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH) (GlobeNewswire)
Jun-27-23 09:56AM	These 2 Strong Buy Penny Stocks Could Soar to $25 (Or Higher), Says Piper Sandler (TipRanks) +6.96%
Jun-16-23 07:30AM	Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023 (GlobeNewswire)
Jun-15-23 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress 2023 (GlobeNewswire)
May-31-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-11-23 07:00AM	Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) +7.03%

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sohn Catherine A.	Director	Mar 17 '25	Buy	5.78	1,000	5,784	1,000	Mar 18 04:15 PM
WEAVER GREGORY L	Chief Financial Officer	Mar 13 '25	Buy	5.20	10,000	51,996	10,000	Mar 14 07:27 AM
Garg Vipin K	President and CEO	Feb 02 '25	Option Exercise	0.00	18,950	0	363,364	Feb 03 08:50 PM
Garg Vipin K	President and CEO	Feb 01 '25	Option Exercise	0.00	16,545	0	351,645	Feb 03 08:50 PM
Garg Vipin K	President and CEO	Jan 30 '25	Option Exercise	0.00	26,775	0	342,696	Feb 03 08:50 PM
Harris Matthew Scott	Chief Medical Officer	Feb 02 '25	Option Exercise	0.00	7,775	0	84,564	Feb 03 08:48 PM
Harris Matthew Scott	Chief Medical Officer	Feb 01 '25	Option Exercise	0.00	6,166	0	78,898	Feb 03 08:48 PM
Harris Matthew Scott	Chief Medical Officer	Jan 30 '25	Option Exercise	0.00	9,275	0	74,000	Feb 03 08:48 PM
Roberts M Scot	Chief Scientific Officer	Feb 02 '25	Option Exercise	0.00	7,775	0	75,536	Feb 03 08:43 PM
Roberts M Scot	Chief Scientific Officer	Feb 01 '25	Option Exercise	0.00	6,166	0	69,562	Feb 03 08:43 PM
Roberts M Scot	Chief Scientific Officer	Jan 30 '25	Option Exercise	0.00	9,275	0	62,921	Feb 03 08:43 PM
Roberts M Scot	Chief Scientific Officer	Jan 25 '25	Option Exercise	0.00	14,600	0	57,910	Jan 28 09:06 PM
Jordt Raymond M	Chief Business Officer	Jan 25 '25	Option Exercise	0.00	14,600	0	36,150	Jan 28 09:05 PM
Harris Matthew Scott	Chief Medical Officer	Jan 25 '25	Option Exercise	0.00	14,600	0	69,719	Jan 28 09:05 PM
Garg Vipin K	President and CEO	Jan 25 '25	Option Exercise	0.00	42,050	0	334,078	Jan 28 09:04 PM
Jordt Raymond M	Chief Business Officer	Jan 01 '25	Option Exercise	0.00	9,375	0	24,035	Jan 03 04:40 PM
Drutz David	Director	Aug 19 '24	Option Exercise	2.55	41,750	106,375	63,708	Aug 20 06:05 PM
Drutz David	Director	Aug 19 '24	Sale	6.90	16,011	110,547	41,958	Aug 20 06:05 PM

Dollar change -10.78
Percentage change -8.92	%

JAZZ Jazz Pharmaceuticals plc daily Stock Chart

Peers: VRTX REGN BIIB INCY GILD BMRN NBIX EXEL UTHR SAGE

| Held by: VTI IJH VB VBR VXF CALF MDY IJJ SPMD VHT

Index	-	P/E	12.65	EPS (ttm)	8.70	Insider Own	4.54%	Shs Outstand	60.63M	Perf Week	-10.48%
Market Cap	6.68B	Forward P/E	4.81	EPS next Y	22.87	Insider Trans	-1.35%	Shs Float	57.97M	Perf Month	-19.36%
Income	560.12M	PEG	2.46	EPS next Q	4.78	Inst Own	97.57%	Short Float	7.80%	Perf Quarter	-11.09%
Sales	4.07B	P/S	1.64	EPS this Y	11.51%	Inst Trans	2.00%	Short Ratio	4.76	Perf Half Y	0.31%
Book/sh	67.52	P/B	1.63	EPS next Y	-1.88%	ROA	4.79%	Short Interest	4.52M	Perf Year	-5.88%
Cash/sh	49.28	P/C	2.23	EPS next 5Y	5.15%	ROE	14.31%	52W Range	99.06 - 148.06	Perf YTD	-10.65%
Dividend Est.	-	P/FCF	4.92	EPS past 5Y	-1.00%	ROI	5.48%	52W High	-25.68%	Beta	0.38
Dividend TTM	-	Quick Ratio	3.99	Sales past 5Y	13.88%	Gross Margin	73.63%	52W Low	11.08%	ATR (14)	4.98
Dividend Ex-Date	-	Current Ratio	4.46	EPS Y/Y TTM	38.88%	Oper. Margin	17.86%	RSI (14)	25.20	Volatility	4.39% 3.28%
Employees	2800	Debt/Eq	1.51	Sales Y/Y TTM	6.12%	Profit Margin	13.77%	Recom	1.30	Target Price	193.82
Option/Short	Yes / Yes	LT Debt/Eq	1.50	EPS Q/Q	129.94%	Payout	0.00%	Rel Volume	2.29	Prev Close	120.82
Sales Surprise	2.84%	EPS Surprise	12.60%	Sales Q/Q	7.53%	Earnings	Feb 25 AMC	Avg Volume	949.34K	Price	110.04
SMA20	-16.87%	SMA50	-16.65%	SMA200	-7.27%	Trades		Volume	2,170,382	Change	-8.92%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-07-25	Upgrade	UBS	Neutral → Buy	$145 → $179
Feb-26-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-13-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$130 → $170
Dec-12-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$140 → $175
Jun-05-24	Initiated	Goldman	Buy	$169
Jan-03-24	Initiated	Robert W. Baird	Outperform	$160
Nov-27-23	Downgrade	UBS	Buy → Neutral	$170 → $135
Sep-29-23	Initiated	Raymond James	Mkt Perform
Jun-12-23	Resumed	Wells Fargo	Equal Weight	$184 → $140
Dec-09-22	Upgrade	Goldman	Neutral → Buy	$192 → $190
Jun-14-22	Initiated	UBS	Buy	$194
Apr-06-22	Downgrade	Goldman	Buy → Neutral	$202 → $196
Nov-19-21	Resumed	Goldman	Buy	$198
Oct-07-21	Resumed	Jefferies	Buy	$172
Oct-05-21	Initiated	Citigroup	Buy	$200
Sep-23-21	Initiated	Needham	Buy	$220
May-19-21	Resumed	JP Morgan	Overweight	$183 → $206
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$186
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$195 → $207
Feb-03-21	Upgrade	Piper Sandler	Neutral → Overweight	$150 → $175

Show Previous Ratings

Apr-04-25 01:10PM	AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication (Zacks) -8.92%
Apr-03-25 11:27AM	SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases (Zacks)
Apr-02-25 11:29AM	AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol (Zacks)
09:33AM	Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 (Zacks)
Apr-01-25 10:55AM	VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates (Zacks)
09:40AM	Loading…
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Mar-31-25 11:40AM	JAZZ or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Mar-29-25 04:15PM	Is Jazz Pharmaceuticals (JAZZ) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Mar-28-25 09:26AM	BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance (Zacks)
Mar-27-25 11:36AM	NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication (Zacks)
11:30AM	Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound? (Zacks)
07:30AM	Franklin Biotechnology Discovery Fund Q4 2024 Commentary (SeekingAlpha)
Mar-26-25 04:15PM	Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference (PR Newswire)
11:51AM	AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint (Zacks)
Mar-25-25 05:39PM	Is Jazz Pharmaceuticals plc (JAZZ) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
09:50AM	Loading…
Mar-24-25 09:50AM	Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term (Zacks)
04:26AM	Zacks.com featured highlights include MPLX LP, Leidos, Jazz Pharmaceuticals, Fortinet and Pilgrim's Pride (Zacks)
Mar-22-25 04:09PM	TPB, ACB and JAZZ: Three Pot Stocks Flowering With Potential Upside (TipRanks)
Mar-21-25 12:04PM	5 High ROE Stocks to Buy as Markets Dip Despite Rate Cut Hopes (Zacks)
Mar-20-25 01:03PM	3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets (SeekingAlpha)
09:38AM	4 Top PEG Stocks Based on GARP Approach to Smart Investing (Zacks)
Mar-19-25 12:14PM	HRMY Down 10.8% in Six Months: How Should You Play the Stock? (Zacks)
09:55AM	Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect? (Zacks)
09:02AM	3 Value Stocks Skating on Thin Ice (StockStory)
07:30AM	Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex (cannabidiol) at American Academy of Neurology Annual Meeting (PR Newswire)
Mar-17-25 11:21AM	Cash In On The Luck Of The Irish With 5 St. Patrick's Day Stocks Near Buy Points (Investor's Business Daily)
07:53AM	Five Irish Stocks Near Buy Points To Add Green To Your Portfolio On St. Patrick's Day (Investor's Business Daily)
Mar-14-25 09:40AM	Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock (Zacks)
Mar-12-25 06:00AM	Bull of the Day: Jazz Pharmaceuticals (JAZZ) (Zacks)
Mar-09-25 06:09PM	Why Chimerix, Inc. (CMRX) Soared Last Week (Insider Monkey)
01:03PM	Loading…
Mar-05-25 01:03PM	Jazz Pharmaceuticals bids for Chimerix in $935m deal (Pharmaceutical Technology)
07:00AM	Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio (PR Newswire)
06:53AM	Jazz expands in oncology with $935M deal for Chimerix (BioPharma Dive)
Mar-04-25 08:07AM	3 Small-Cap Stocks Skating on Thin Ice (StockStory)
Mar-03-25 06:51PM	Jazz Pharmaceuticals plc (JAZZ): Among the Cash-Rich Mid Cap Stocks to Buy Now (Insider Monkey)
12:20PM	Earnings Estimates Moving Higher for Jazz (JAZZ): Time to Buy? (Zacks)
09:55AM	Wall Street Analysts See a 29.63% Upside in Jazz (JAZZ): Can the Stock Really Move This High? (Zacks)
Feb-28-25 09:45AM	Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
09:15AM	International Markets and Jazz (JAZZ): A Deep Dive for Investors (Zacks)
Feb-26-25 10:53AM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
09:40AM	Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term (Zacks)
02:14AM	Jazz Pharmaceuticals PLC (JAZZ) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Feb-25-25 06:30PM	Compared to Estimates, Jazz (JAZZ) Q4 Earnings: A Look at Key Metrics (Zacks)
05:45PM	Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates (Zacks)
05:33PM	Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 Sales (StockStory)
04:43PM	Jazz: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance (PR Newswire)
Feb-24-25 08:02AM	Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect (StockStory)
Feb-20-25 04:15PM	Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference (PR Newswire)
09:15AM	Jazz (JAZZ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
Feb-12-25 09:25AM	Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains? (Zacks)
Feb-11-25 04:15PM	Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025 (PR Newswire) +5.24%
Feb-05-25 12:10PM	Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again (Zacks)
Jan-15-25 01:57PM	JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline (Clinical Trials Arena)
01:54PM	Jazz Pharmaceuticals plc (JAZZ): Analysts Recommend This 52-Week High Stocks Now (Insider Monkey)
Dec-17-24 04:15PM	Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-16-24 04:05PM	Jazz Pharmaceuticals Announces CEO Succession Plan (PR Newswire)
Dec-13-24 08:00AM	Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch (TipRanks)
Dec-06-24 04:05PM	Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting (PR Newswire)
11:31AM	Jazz (JAZZ) Up 3.4% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-05-24 07:45AM	Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera) (PR Newswire)
Dec-04-24 04:15PM	Jazz Pharmaceuticals Announces Ziihera (zanidatamab-hrii) Investor Webcast on December 11, 2024 (PR Newswire)
Dec-03-24 07:49AM	Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting (PR Newswire)
Nov-29-24 09:55AM	Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet (Zacks)
Nov-28-24 05:50AM	Why Jazz Pharmaceuticals (JAZZ) Is One of the Most Undervalued Pot Stocks to Buy? (Insider Monkey)
Nov-22-24 06:36AM	Jazz Pharmaceuticals price target lowered to $163 from $166 at Piper Sandler (TipRanks)
Nov-20-24 07:19PM	Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) (PR Newswire)
Nov-19-24 04:05PM	Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference (PR Newswire)
09:40AM	Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock? (Zacks)
08:29AM	Silver Ring Value Partners: Jazz Pharmaceuticals (JAZZ) Is a High Uncertainty With Low Risk Investment (Insider Monkey)
Nov-18-24 08:30AM	Is Jazz Pharmaceuticals plc (JAZZ) the Best Immunotherapy Stock to Buy Now? (Insider Monkey)
Nov-14-24 08:46AM	Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock? (Zacks)
Nov-13-24 12:00PM	Jazz (JAZZ) Upgraded to Buy: Here's Why (Zacks)
09:55AM	Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High? (Zacks)
Nov-11-24 12:29PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
09:15AM	Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know (Zacks)
Nov-08-24 05:00AM	Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value (BioPharma Dive)
Nov-07-24 07:22PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) +6.75%
02:20AM	Jazz Pharmaceuticals PLC (JAZZ) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-06-24 07:00PM	Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics (Zacks)
05:55PM	Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates (Zacks)
04:49PM	Jazz: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results (PR Newswire)
Nov-04-24 09:16AM	Insights Into Jazz (JAZZ) Q3: Wall Street Projections for Key Metrics (Zacks)
Oct-31-24 04:05PM	Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia (PR Newswire)
Oct-30-24 10:01AM	Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-27-24 02:00AM	Jazz Pharmaceuticals plc (JAZZ): Among the Best Stocks to Buy for High Returns in 2024 (Insider Monkey)
Oct-24-24 08:30AM	Jazz Pharmaceuticals price target raised to $179 from $175 at RBC Capital (TipRanks)
Oct-23-24 04:15PM	Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024 (PR Newswire)
Oct-18-24 04:34PM	Avadel wins FDA approval for narcolepsy drug Lumryz in children (Pharmaceutical Technology)
05:21AM	Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker (Motley Fool)
Oct-17-24 09:55AM	Wall Street Analysts Think Jazz (JAZZ) Could Surge 51.8%: Read This Before Placing a Bet (Zacks)
09:40AM	Are Investors Undervaluing Jazz Pharmaceuticals (JAZZ) Right Now? (Zacks)
Oct-16-24 03:55PM	Is Jazz Pharmaceuticals plc (JAZZ) the Most Promising Biotech Stock According to Hedge Funds? (Insider Monkey)
08:54AM	Is Jazz Pharmaceuticals (JAZZ) the Best Small-Cap Value Stock to Buy According to Hedge Funds? (Insider Monkey)
07:35AM	Jazz Pharmaceuticals Zepzelca combination meets endpoints in lung cancer trial (TipRanks)
Oct-15-24 11:50AM	Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer (Benzinga) +5.63%
10:31AM	PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (PR Newswire)
07:30AM	Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (PR Newswire)
06:47AM	Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data (BioPharma Dive)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
COZADD BRUCE C	Chairman & CEO	Apr 01 '25	Sale	123.75	1,500	185,625	440,307	Apr 03 05:32 PM
COZADD BRUCE C	Officer	Apr 01 '25	Proposed Sale	125.31	2,000	250,625		Apr 01 04:32 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Mar 10 '25	Sale	138.41	2,403	332,605	79,621	Mar 12 02:24 PM
Carr Patricia	SVP, Chief Accounting Officer	Mar 10 '25	Sale	137.81	1,140	157,103	7,012	Mar 11 06:17 PM
Iannone Robert	Officer	Mar 10 '25	Proposed Sale	145.00	1,767	256,215		Mar 10 06:01 PM
Carr Patricia	Officer	Mar 10 '25	Proposed Sale	137.81	1,140	157,103		Mar 10 05:36 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Mar 07 '25	Sale	138.60	7,080	981,298	82,024	Mar 07 06:49 PM
ROBERT IANNONE	Officer	Mar 07 '25	Proposed Sale	138.73	5,466	758,305		Mar 07 05:14 PM
Iannone Robert	Officer	Mar 07 '25	Proposed Sale	142.26	4,017	571,476		Mar 07 05:04 PM
Henderson Mary Elizabeth	Officer	Mar 07 '25	Proposed Sale	139.00	1,295	180,005		Mar 07 03:15 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '25	Option Exercise	113.77	4,813	547,562	12,737	Mar 03 07:21 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '25	Sale	144.42	4,813	695,075	8,237	Mar 03 07:21 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 28 '25	Sale	143.29	773	110,767	9,485	Mar 03 07:21 PM
Patil Neena M	EVP & Chief Legal Officer	Feb 27 '25	Sale	144.87	3,800	550,506	33,318	Mar 03 07:18 PM
COZADD BRUCE C	Chairman & CEO	Mar 03 '25	Sale	144.25	6,500	937,625	464,058	Mar 03 07:13 PM
COZADD BRUCE C	Officer	Mar 03 '25	Proposed Sale	144.25	6,500	937,625		Mar 03 04:44 PM
Carr Patricia	Officer	Feb 28 '25	Proposed Sale	143.30	773	110,767		Feb 28 05:43 PM
Carr Patricia	Officer	Feb 27 '25	Proposed Sale	139.00	1,641	228,099		Feb 27 08:05 PM
Carr Patricia	Officer	Feb 27 '25	Proposed Sale	144.42	4,813	695,075		Feb 27 05:04 PM
Patil Neena M	Officer	Feb 27 '25	Proposed Sale	144.87	3,800	550,518		Feb 27 04:56 PM
COZADD BRUCE C	Chairman & CEO	Feb 03 '25	Sale	122.31	1,500	183,465	439,744	Feb 05 05:41 PM
COZADD BRUCE C	Officer	Feb 03 '25	Proposed Sale	122.31	1,500	183,465		Feb 03 05:04 PM
COZADD BRUCE C	Chairman & CEO	Jan 02 '25	Sale	123.43	1,500	185,145	425,525	Jan 06 04:22 PM
COZADD BRUCE C	Officer	Jan 02 '25	Proposed Sale	123.43	1,500	185,145		Jan 02 05:00 PM
COZADD BRUCE C	Chairman & CEO	Dec 02 '24	Sale	121.17	2,000	242,340	427,025	Dec 04 05:24 PM
Carr Patricia	SVP, Chief Accounting Officer	Dec 02 '24	Sale	122.49	53	6,492	6,596	Dec 04 05:20 PM
COZADD BRUCE C	Officer	Dec 02 '24	Proposed Sale	121.17	2,000	242,340		Dec 02 06:05 PM
Carr Patricia	Officer	Dec 02 '24	Proposed Sale	122.49	53	6,492		Dec 02 04:20 PM
Patil Neena M	EVP & Chief Legal Officer	Nov 08 '24	Sale	123.41	3,700	456,617	33,048	Nov 13 05:44 PM
Patil Neena M	Officer	Nov 08 '24	Proposed Sale	123.41	3,700	456,632		Nov 08 05:55 PM
COZADD BRUCE C	Chairman & CEO	Nov 01 '24	Sale	110.84	1,000	110,840	428,976	Nov 05 05:00 PM
COZADD BRUCE C	Officer	Nov 01 '24	Proposed Sale	110.84	1,000	110,840		Nov 01 03:19 PM
Henderson Mary Elizabeth	SVP, Technical Operations	Sep 06 '24	Sale	108.30	1,410	152,703	14,531	Sep 11 11:38 AM
Henderson Mary Elizabeth	Officer	Sep 06 '24	Proposed Sale	110.00	2,691	296,010		Sep 05 07:50 PM
Winningham Rick E	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:57 PM
Smith Mark Douglas	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:55 PM
RIEDEL NORBERT G	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:49 PM
ORiordan Anne	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:42 PM
O'Keefe Kenneth W	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:35 PM
McSharry Heather Ann	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:29 PM
Cook Jennifer E.	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:19 PM
Sohn Catherine A.	Director	Aug 05 '24	Proposed Sale	111.00	3,075	341,325		Aug 02 04:20 PM
Carr Patricia	SVP, Chief Accounting Officer	Jun 07 '24	Sale	108.83	163	17,738	6,596	Jun 11 08:15 PM
Patil Neena M	EVP & Chief Legal Officer	May 03 '24	Sale	109.65	5,000	548,250	36,629	May 07 05:31 PM

ALT

Altimmune Inc

JAZZ

Jazz Pharmaceuticals plc

Upgrade your FINVIZ experience